Important Dates

no event

Latest News

SOM Innovation Biotech European Study endorsed* by EHDN

Study aims and goal: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. No. of study participants and sites: This Phase IIb study aims to recruit participants from 22 sites in France, Germany, Italy, Poland, Spain, […]

Weiterlesen…

Joint working Genetic Modifiers Working Group, Genetic Counseling & Testing Working Group and Incidental Findings Task Force meeting

Meeting notice: Joint working Genetic Modifiers Working Group, Genetic Counseling & Testing Working Group and Incidental Findings Task Force meeting Thursday 15th September 2022, 13.00 – 17.00 Location: room Magenta B, Bologna Congressi S.r.l (if you would like information about joining remotely please let us know) Application of genetic modifier of Huntington’s disease data in […]

Weiterlesen…

HD Human Biology Project

The Huntington’s Disease Society of America has adopted a patient-centric research strategy to push the field closer to meeting our goal of identifying effective therapies. The HD Human Biology Project is the cornerstone of this strategy. … […]

Weiterlesen…